Selected research
Industry Research
Eltrombopag Drugs Industry Research Report 2026
Market perspective
The global Eltrombopag Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Eltrombopag Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Eltrombopag Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Eltrombopag Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Eltrombopag Drugs include Actavis Laboratories, Amneal Pharmaceuticals, Annora Pharma, Hetero, Novartis, Teva, Changzhou Pharmaceutical Factory, Guangdong Longfu Pharmaceutical and Ningbo Menovo Tiankang Pharmaceutical, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Eltrombopag Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Eltrombopag Drugs Market by Company
Actavis Laboratories
Amneal Pharmaceuticals
Annora Pharma
Hetero
Novartis
Teva
Changzhou Pharmaceutical Factory
Guangdong Longfu Pharmaceutical
Ningbo Menovo Tiankang Pharmaceutical
Qilu Pharmaceutical
Shandong Jewim Pharmaceutical
Sichuan Kelun Pharmaceutical
Grand Pharmaceutical
Zhejiang Hisun Pharmaceutical
Chia Tai Tianqing Pharmaceutical
Eltrombopag Drugs Segment by Type
Tablets
Oral Suspension
Eltrombopag Drugs Segment by Application
Hospital and Clinic
Pharmacy
Other
Eltrombopag Drugs Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Eltrombopag Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Eltrombopag Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Eltrombopag Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Eltrombopag Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Eltrombopag Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Eltrombopag Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Tablets
- Oral Suspension
Applications
- Hospital and Clinic
- Pharmacy
- Other
Companies covered
- Actavis Laboratories
- Amneal Pharmaceuticals
- Annora Pharma
- Hetero
- Novartis
- Teva
- Changzhou Pharmaceutical Factory
- Guangdong Longfu Pharmaceutical
- Ningbo Menovo Tiankang Pharmaceutical
- Qilu Pharmaceutical
- Shandong Jewim Pharmaceutical
- Sichuan Kelun Pharmaceutical
- Grand Pharmaceutical
- Zhejiang Hisun Pharmaceutical
- Chia Tai Tianqing Pharmaceutical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Eltrombopag Drugs Market Size (2021-2032)
- 2.2.2 Global Eltrombopag Drugs Sales (2021-2032)
- 2.2.3 Global Eltrombopag Drugs Market Average Price (2021-2032)
- 2.3 Eltrombopag Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Tablets
- 2.3.3 Oral Suspension
- 2.4 Eltrombopag Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital and Clinic
- 2.4.3 Pharmacy
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Eltrombopag Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Eltrombopag Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Eltrombopag Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Eltrombopag Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Eltrombopag Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Eltrombopag Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Eltrombopag Drugs, Product Type & Application
- 3.8 Global Manufacturers of Eltrombopag Drugs, Established Date
- 3.9 Global Eltrombopag Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Actavis Laboratories
- 4.1.1 Actavis Laboratories Company Information
- 4.1.2 Actavis Laboratories Business Overview
- 4.1.3 Actavis Laboratories Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Actavis Laboratories Eltrombopag Drugs Product Portfolio
- 4.1.5 Actavis Laboratories Recent Developments
- 4.2 Amneal Pharmaceuticals
- 4.2.1 Amneal Pharmaceuticals Company Information
- 4.2.2 Amneal Pharmaceuticals Business Overview
- 4.2.3 Amneal Pharmaceuticals Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amneal Pharmaceuticals Eltrombopag Drugs Product Portfolio
- 4.2.5 Amneal Pharmaceuticals Recent Developments
- 4.3 Annora Pharma
- 4.3.1 Annora Pharma Company Information
- 4.3.2 Annora Pharma Business Overview
- 4.3.3 Annora Pharma Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Annora Pharma Eltrombopag Drugs Product Portfolio
- 4.3.5 Annora Pharma Recent Developments
- 4.4 Hetero
- 4.4.1 Hetero Company Information
- 4.4.2 Hetero Business Overview
- 4.4.3 Hetero Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Hetero Eltrombopag Drugs Product Portfolio
- 4.4.5 Hetero Recent Developments
- 4.5 Novartis
- 4.5.1 Novartis Company Information
- 4.5.2 Novartis Business Overview
- 4.5.3 Novartis Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Novartis Eltrombopag Drugs Product Portfolio
- 4.5.5 Novartis Recent Developments
- 4.6 Teva
- 4.6.1 Teva Company Information
- 4.6.2 Teva Business Overview
- 4.6.3 Teva Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Teva Eltrombopag Drugs Product Portfolio
- 4.6.5 Teva Recent Developments
- 4.7 Changzhou Pharmaceutical Factory
- 4.7.1 Changzhou Pharmaceutical Factory Company Information
- 4.7.2 Changzhou Pharmaceutical Factory Business Overview
- 4.7.3 Changzhou Pharmaceutical Factory Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Changzhou Pharmaceutical Factory Eltrombopag Drugs Product Portfolio
- 4.7.5 Changzhou Pharmaceutical Factory Recent Developments
- 4.8 Guangdong Longfu Pharmaceutical
- 4.8.1 Guangdong Longfu Pharmaceutical Company Information
- 4.8.2 Guangdong Longfu Pharmaceutical Business Overview
- 4.8.3 Guangdong Longfu Pharmaceutical Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Guangdong Longfu Pharmaceutical Eltrombopag Drugs Product Portfolio
- 4.8.5 Guangdong Longfu Pharmaceutical Recent Developments
- 4.9 Ningbo Menovo Tiankang Pharmaceutical
- 4.9.1 Ningbo Menovo Tiankang Pharmaceutical Company Information
- 4.9.2 Ningbo Menovo Tiankang Pharmaceutical Business Overview
- 4.9.3 Ningbo Menovo Tiankang Pharmaceutical Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Ningbo Menovo Tiankang Pharmaceutical Eltrombopag Drugs Product Portfolio
- 4.9.5 Ningbo Menovo Tiankang Pharmaceutical Recent Developments
- 4.10 Qilu Pharmaceutical
- 4.10.1 Qilu Pharmaceutical Company Information
- 4.10.2 Qilu Pharmaceutical Business Overview
- 4.10.3 Qilu Pharmaceutical Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Qilu Pharmaceutical Eltrombopag Drugs Product Portfolio
- 4.10.5 Qilu Pharmaceutical Recent Developments
- 4.11 Shandong Jewim Pharmaceutical
- 4.11.1 Shandong Jewim Pharmaceutical Company Information
- 4.11.2 Shandong Jewim Pharmaceutical Business Overview
- 4.11.3 Shandong Jewim Pharmaceutical Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Shandong Jewim Pharmaceutical Eltrombopag Drugs Product Portfolio
- 4.11.5 Shandong Jewim Pharmaceutical Recent Developments
- 4.12 Sichuan Kelun Pharmaceutical
- 4.12.1 Sichuan Kelun Pharmaceutical Company Information
- 4.12.2 Sichuan Kelun Pharmaceutical Business Overview
- 4.12.3 Sichuan Kelun Pharmaceutical Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Sichuan Kelun Pharmaceutical Eltrombopag Drugs Product Portfolio
- 4.12.5 Sichuan Kelun Pharmaceutical Recent Developments
- 4.13 Grand Pharmaceutical
- 4.13.1 Grand Pharmaceutical Company Information
- 4.13.2 Grand Pharmaceutical Business Overview
- 4.13.3 Grand Pharmaceutical Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Grand Pharmaceutical Eltrombopag Drugs Product Portfolio
- 4.13.5 Grand Pharmaceutical Recent Developments
- 4.14 Zhejiang Hisun Pharmaceutical
- 4.14.1 Zhejiang Hisun Pharmaceutical Company Information
- 4.14.2 Zhejiang Hisun Pharmaceutical Business Overview
- 4.14.3 Zhejiang Hisun Pharmaceutical Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Zhejiang Hisun Pharmaceutical Eltrombopag Drugs Product Portfolio
- 4.14.5 Zhejiang Hisun Pharmaceutical Recent Developments
- 4.15 Chia Tai Tianqing Pharmaceutical
- 4.15.1 Chia Tai Tianqing Pharmaceutical Company Information
- 4.15.2 Chia Tai Tianqing Pharmaceutical Business Overview
- 4.15.3 Chia Tai Tianqing Pharmaceutical Eltrombopag Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Chia Tai Tianqing Pharmaceutical Eltrombopag Drugs Product Portfolio
- 4.15.5 Chia Tai Tianqing Pharmaceutical Recent Developments
5 Global Eltrombopag Drugs Market Scenario by Region
- 5.1 Global Eltrombopag Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Eltrombopag Drugs Sales by Region: 2021-2032
- 5.2.1 Global Eltrombopag Drugs Sales by Region: 2021-2026
- 5.2.2 Global Eltrombopag Drugs Sales by Region: 2027-2032
- 5.3 Global Eltrombopag Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Eltrombopag Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Eltrombopag Drugs Revenue by Region: 2027-2032
- 5.4 North America Eltrombopag Drugs Market Facts & Figures by Country
- 5.4.1 North America Eltrombopag Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Eltrombopag Drugs Sales by Country (2021-2032)
- 5.4.3 North America Eltrombopag Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Eltrombopag Drugs Market Facts & Figures by Country
- 5.5.1 Europe Eltrombopag Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Eltrombopag Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Eltrombopag Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Eltrombopag Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Eltrombopag Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Eltrombopag Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Eltrombopag Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Eltrombopag Drugs Market Facts & Figures by Country
- 5.7.1 South America Eltrombopag Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Eltrombopag Drugs Sales by Country (2021-2032)
- 5.7.3 South America Eltrombopag Drugs Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Eltrombopag Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Eltrombopag Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Eltrombopag Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Eltrombopag Drugs Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Eltrombopag Drugs Sales by Type (2021-2032)
- 6.1.1 Global Eltrombopag Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Eltrombopag Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Eltrombopag Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Eltrombopag Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Eltrombopag Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Eltrombopag Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Eltrombopag Drugs Sales by Application (2021-2032)
- 7.1.1 Global Eltrombopag Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Eltrombopag Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Eltrombopag Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Eltrombopag Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Eltrombopag Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Eltrombopag Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Eltrombopag Drugs Value Chain Analysis
- 8.1.1 Eltrombopag Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Eltrombopag Drugs Production Mode & Process
- 8.2 Eltrombopag Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Eltrombopag Drugs Distributors
- 8.2.3 Eltrombopag Drugs Customers
9 Global Eltrombopag Drugs Analyzing Market Dynamics
- 9.1 Eltrombopag Drugs Industry Trends
- 9.2 Eltrombopag Drugs Industry Drivers
- 9.3 Eltrombopag Drugs Industry Opportunities and Challenges
- 9.4 Eltrombopag Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst